{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/merck-mrk/",
 "dataUrl": "https://clearank.com/stock/merck-mrk/data.json",
 "title": "Merck (MRK) Stock Forecast & Price Target (2026)",
 "description": "Merck & Co., Inc. (MRK) stock: Healthcare, Drug Manufacturers - General. $357.4B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Merck & Co., Inc. (MRK)",
 "published": "2026-06-07T09:08:55+00:00",
 "modified": "2026-09-15T15:06:03.014+00:00",
 "generated": "2026-09-16T10:59:16.312Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "MRK",
  "name": "Merck & Co., Inc.",
  "type": "Common Stock",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Drug Manufacturers - General",
  "country": "United States",
  "website": "https://www.merck.com"
 },
 "quote": {
  "price": 143.17,
  "previousClose": 144.85,
  "change": -1.68,
  "changePercent": -1.16,
  "open": 143.96,
  "high": 144.03,
  "low": 142.32,
  "volume": 64863,
  "averageVolume": 7315906,
  "marketCap": 357369836436,
  "fiftyTwoWeekHigh": 156.92,
  "fiftyTwoWeekLow": 77.58,
  "marketOpen": false,
  "asOf": "2026-09-15T15:06:02.000Z"
 },
 "statistics": {
  "pe": 116.276,
  "eps": 1.25,
  "dividendYield": 0.023752139439030352,
  "beta": 0.226,
  "priceToSales": 5.386758,
  "priceToBook": 8.556752,
  "revenueTtm": 66568998912,
  "grossMargin": 0.7353525621725778,
  "returnOnEquity": 0.06961
 },
 "technicals": {
  "rsi": 22.65,
  "macd": 2.37,
  "sma50": 136.68,
  "sma200": 119.82,
  "rsiSignal": "Oversold",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Sell",
  "score": 21,
  "consensus": "Sell",
  "fairValue": 143.17,
  "analystTarget": 152.5,
  "analystCount": 28,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-15T15:06:02.000Z",
  "priceAtAnalysis": 143.17,
  "volatility": {
   "daily": 2.73,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Bearish",
  "conservativeEntry": 146.03,
  "aggressiveEntry": 143.17,
  "stopLoss": 152.6,
  "stopLossPercent": 4.5,
  "targets": [
   138.73,
   131.43,
   124.13
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 114.87,
    "base": 155.01,
    "upside90th": 209.18
   },
   {
    "year": 2028,
    "downside10th": 109.85,
    "base": 167.84,
    "upside90th": 256.42
   },
   {
    "year": 2029,
    "downside10th": 108.14,
    "base": 181.72,
    "upside90th": 305.38
   },
   {
    "year": 2030,
    "downside10th": 108.05,
    "base": 196.75,
    "upside90th": 358.29
   },
   {
    "year": 2031,
    "downside10th": 108.99,
    "base": 213.03,
    "upside90th": 416.36
   },
   {
    "year": 2032,
    "downside10th": 110.7,
    "base": 230.65,
    "upside90th": 480.58
   },
   {
    "year": 2033,
    "downside10th": 113.01,
    "base": 249.73,
    "upside90th": 551.86
   },
   {
    "year": 2034,
    "downside10th": 115.84,
    "base": 270.39,
    "upside90th": 631.13
   },
   {
    "year": 2035,
    "downside10th": 119.13,
    "base": 292.75,
    "upside90th": 719.4
   },
   {
    "year": 2036,
    "downside10th": 122.87,
    "base": 316.97,
    "upside90th": 817.72
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "MRK Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$143.96",
    "Day Range": "$142.32 to $144.03",
    "Prev Close": "$144.85",
    "Volume": "64.9K",
    "52-Week Range": "$77.58 to $156.92",
    "Market Cap": "$357.37B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Trading at a significant premium to sector peers (+265%), suggesting market expectations for superior growth or market position."
   ]
  },
  {
   "id": "financials",
   "title": "MRK Financial Performance",
   "text": [
    "Analysis: In the last 4 quarters, MRK beat estimates 4 times. The stock rose 4 times the next day. Price tends to react positively to beats."
   ]
  },
  {
   "id": "analysis",
   "title": "MRK Analysis",
   "text": [
    "Merck & Co. (MRK) is trading below its 20-day EMA of $145.34, indicating short-term weakness, but remains above its 50-day SMA of $136.68 and 200-day SMA of $119.82, suggesting that the longer-term uptrend may still be intact. The Relative Strength Index (RSI) is at 22.65, firmly in oversold territory, which could signal a potential bounce, but also indicates strong downward momentum. The MACD is at 2.37, suggesting bullish momentum, but this is contradicted by the RSI and the price action relative to the short-term EMA. Key support is seen at the 50-day SMA of $136.68, while resistance lies at the 20-day EMA of $145.34 and the current price of $143.17. Volume on the latest trading day was significantly below average, which is typical for a stock in an oversold condition. The chart structure, with the price below the 20-day EMA and the RSI significantly oversold, points towards a potential short-term pullback or consolidation. However, the sustained trading above longer-term moving averages suggests that the broader trend has not yet turned bearish. Investors should watch for a potential reversal pattern or a sustained move back above the 20-day EMA to confirm any upward price action.",
    "Insiders have sold $72.4 million worth of stock, indicating a significant lack of confidence in the company's near-term prospects.",
    "The RSI is at 22.65, signaling that the stock is technically oversold and could experience further downward price movement.",
    "Merck & Co. reported a 50% EPS surprise in the quarter to June 2026, beating estimates and potentially signaling improving operational performance.",
    "A majority of Wall Street analysts maintain a 'Buy' rating, with a median price target of $152.50, suggesting potential upside.",
    "Merck & Co. (MRK) faces a challenging near-term outlook due to significant insider selling and oversold technical conditions. The current price action below the 20-day EMA and a significantly oversold RSI suggest a potential for further downside, despite the stock trading above its longer-term moving averages. The high valuation multiples, including a P/E of 116.28, further add to concerns. The base case scenario for MRK anticipates a period of consolidation or potential decline, given the bearish insider signal and stretched valuation. Upside catalysts would need to overcome the current negative sentiment, potentially driven by stronger-than-expected clinical trial results or significant pipeline advancements not yet reflected in current estimates. Conversely, continued insider selling, negative earnings surprises, or increased competition could exacerbate downward pressure, pushing the stock towards its 50-day SMA support level."
   ],
   "lists": {
    "ProTips": [
     "Monitor insider transactions closely; the current heavy net selling signal suggests caution is warranted.",
     "Given the oversold RSI of 22.65, traders may look for a short-term bounce, but the overall trend remains uncertain without a clear catalyst.",
     "The high P/E ratio of 116.28 and negative operating margin warrant a conservative approach to valuation, especially considering the sector median P/E of 31.9."
    ]
   },
   "catalysts": [
    {
     "type": "Bearish",
     "title": "Heavy Insider Selling Pressure",
     "text": "Insiders have sold $72.4 million worth of stock, indicating a significant lack of confidence in the company's near-term prospects.",
     "source": "Insider Trading Data"
    },
    {
     "type": "Bearish",
     "title": "Oversold Technical Conditions",
     "text": "The RSI is at 22.65, signaling that the stock is technically oversold and could experience further downward price movement.",
     "source": "Technical Analysis"
    },
    {
     "type": "Bullish",
     "title": "Positive Earnings Surprise in Latest Quarter",
     "text": "Merck & Co. reported a 50% EPS surprise in the quarter to June 2026, beating estimates and potentially signaling improving operational performance.",
     "source": "Earnings Report"
    },
    {
     "type": "Bullish",
     "title": "Wall Street 'Buy' Consensus",
     "text": "A majority of Wall Street analysts maintain a 'Buy' rating, with a median price target of $152.50, suggesting potential upside.",
     "source": "Analyst Ratings"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Merck & Co. (MRK) presents a mixed fundamental picture, with a high P/E ratio of 116.28, significantly above the Healthcare sector median of 31.9, suggesting the stock is trading at a premium. Its Price-to-Sales ratio stands at 5.39, also above the sector median of 3.7. The company's profit margin is 4.77%, which is lower than the sector median of 6.9%, and its operating margin is negative at -0.24%. Return on Equity (ROE) is reported at 6.96%, aligning with the sector median. Despite these valuation concerns, forward estimates show potential for growth, with next year's EPS projected at $9.55 and revenue growth expected to be around 5.00% in the next year. The company's debt-to-equity ratio is 1.28, which is higher than the sector average. While the company has a substantial dividend yield of 2.35%, the high P/E and negative operating margin raise questions about the sustainability of its current valuation, especially when compared to sector averages.",
    "Merck & Co. (MRK) has shown mixed recent earnings performance. The most recent quarter to June 2026 reported an EPS of -$0.13, which was a 50% surprise compared to an estimated -$0.26, and the stock saw a 0.26% price increase. Prior to this, the quarter to March 2026 also beat estimates with an EPS of -$1.28 versus an expected -$1.47, leading to a 2.73% stock price gain. However, the company has a history of negative EPS estimates for the current and next quarters, with current year EPS estimated at $2.75 and next year's at $9.55. Revenue growth has been modest, with current quarter estimates showing 0.00% year-over-year growth.",
    "Merck & Co. (MRK) faces significant risks stemming from heavy insider selling, with $72.4 million in net sales, indicating a lack of confidence from management. The stock is also technically oversold with an RSI of 22.65, suggesting potential for further price declines despite longer-term moving averages remaining supportive. Also, the company's valuation appears stretched, with a P/E ratio of 116.28 significantly exceeding the sector median, and a negative operating margin raises concerns about profitability."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "357.37B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "116.28"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "1.25"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "2.35%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "156.92"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "77.58"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bullish RSI Oversold SMA Cross Bullish Price vs SMA Bullish MACD Bullish Golden Cross in effect with the 50-day SMA ($136.68) above the 200-day SMA ($119.82), price action is firmly bullish above key moving averages, RSI at 22.7 suggests oversold conditions; potential bounce setup."
   ],
   "facts": {
    "RSI": "Oversold",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "22.65"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "2.37"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "136.68"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "119.82"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.16",
    "Correlation with Nasdaq 100 (QQQ)": "+0.04",
    "Correlation with Bitcoin (BTC)": "-0.10",
    "Correlation with Gold (XAU)": "+0.06"
   }
  },
  {
   "id": "trade-plans",
   "title": "MRK Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for rally",
    "Higher risk, chasing the move",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (22.7) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$138.73",
    "TARGET 2": "$131.43",
    "TARGET 3": "$124.13",
    "STOP LOSS": "$152.60"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+0.75%",
    "Average Feb return": "-2.04%",
    "Average Mar return": "+0.69%",
    "Average Apr return": "+0.64%",
    "Average May return": "+0.70%",
    "Average Jun return": "+2.44%",
    "Average Jul return": "-1.47%",
    "Average Aug return": "+3.58%",
    "Average Sep return": "-1.39%",
    "Average Oct return": "-1.36%",
    "Average Nov return": "+4.12%",
    "Average Dec return": "+1.05%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "2.73%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in MRK in September 2016 would be worth about $24,335 today, compared with about $35,344 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in MRK today could grow to about $22,139 by 2036 in the base case, with a bull case near $57,115 and a bear case around $8,582. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "MRK Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $197 for MRK by 2030 in the base case, from $143 today (1.4x over 4 years). The downside path ends near $108. These are outcomes of a Monte Carlo simulation run on MRK's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using MRK's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "MRK simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$115",
        "$155",
        "$209"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$110",
        "$168",
        "$256"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$108",
        "$182",
        "$305"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$108",
        "$197",
        "$358"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$109",
        "$213",
        "$416"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$111",
        "$231",
        "$481"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$113",
        "$250",
        "$552"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$116",
        "$270",
        "$631"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$119",
        "$293",
        "$719"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$123",
        "$317",
        "$818"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "RGNX Regenxbio Inc. NASDAQ $7.95 -8.57%",
     "url": "https://clearank.com/stock/rgnx-stock-analysis/"
    },
    {
     "text": "TLRY Tilray Brands Inc. NASDAQ $3.99 -3.62%",
     "url": "https://clearank.com/stock/tilray-brands-tlry/"
    },
    {
     "text": "RMD ResMed Inc. NYSE $229.44 +2.89%",
     "url": "https://clearank.com/stock/rmd-stock-analysis/"
    },
    {
     "text": "BSX Boston Scientific Corp. NYSE $43.87 -2.62%",
     "url": "https://clearank.com/stock/boston-scientific-bsx/"
    },
    {
     "text": "REPL Replimune Group, Inc. NASDAQ $13.03 -0.61%",
     "url": "https://clearank.com/stock/repl-stock-analysis/"
    },
    {
     "text": "VRTX Vertex Pharmaceuticals Incorporated NASDAQ $514.63 -0.94%",
     "url": "https://clearank.com/stock/vertex-vrtx/"
    },
    {
     "text": "CVS CVS Health Corporation NYSE $94.49 -1.11%",
     "url": "https://clearank.com/stock/cvs-health-cvs/"
    },
    {
     "text": "LEGN Legend Biotech Corporation NASDAQ $17.67 -4.64%",
     "url": "https://clearank.com/stock/legend-biotech-legn/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Compare MRK",
   "links": [
    {
     "text": "PFE vs MRK Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/pfe-vs-mrk/"
    },
    {
     "text": "Junior Gold Miners (GDXJ) vs Silver Miners (SIL) Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/gdxj-vs-sil/"
    },
    {
     "text": "VGT vs SMH Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/vgt-vs-smh/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "MRK Insider Trading Analysis",
   "facts": {
    "Bought": "None",
    "Sold": "$72.4M",
    "Insiders": "14",
    "Avg Transaction": "$3.3M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in MRK",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Oct 31, 2022",
       "cells": [
        "FRAZIER KENNETH C Officer and Director",
        "Sell",
        "867.1K",
        "$87.1M"
       ]
      },
      {
       "label": "Nov 2, 2022",
       "cells": [
        "FRAZIER KENNETH C Officer and Director",
        "Sell",
        "600.0K",
        "$59.9M"
       ]
      },
      {
       "label": "Nov 9, 2021",
       "cells": [
        "FRAZIER KENNETH C Officer and Director",
        "Sell",
        "663.9K",
        "$54.6M"
       ]
      },
      {
       "label": "Nov 4, 2022",
       "cells": [
        "FRAZIER KENNETH C Officer and Director",
        "Sell",
        "470.0K",
        "$46.4M"
       ]
      },
      {
       "label": "Feb 14, 2024",
       "cells": [
        "DAVIS ROBERT M Chief Executive Officer",
        "Sell",
        "235.0K",
        "$29.5M"
       ]
      },
      {
       "label": "Nov 7, 2022",
       "cells": [
        "FRAZIER KENNETH C Officer and Director",
        "Sell",
        "235.8K",
        "$23.5M"
       ]
      },
      {
       "label": "Nov 9, 2020",
       "cells": [
        "FRAZIER KENNETH C Chief Executive Officer",
        "Sell",
        "280.0K",
        "$22.8M"
       ]
      },
      {
       "label": "Nov 1, 2018",
       "cells": [
        "SCHECHTER ADAM H Officer",
        "Sell",
        "277.9K",
        "$20.5M"
       ]
      },
      {
       "label": "Oct 5, 2020",
       "cells": [
        "DAVIS ROBERT M Chief Financial Officer",
        "Sell",
        "251.3K",
        "$20.4M"
       ]
      },
      {
       "label": "Oct 2, 2018",
       "cells": [
        "FRAZIER KENNETH C Chief Executive Officer",
        "Sell",
        "279.9K",
        "$20.2M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Merck+%26+Co.%2C+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "Is Merck & Co. (MRK) stock a buy right now?",
   "answer": "Merck & Co. (MRK) is currently rated as a Sell based on significant insider selling and oversold technical conditions. While Wall Street analysts have a 'Buy' consensus with a median price target of $152.50, the stock's high P/E ratio and negative operating margin present fundamental concerns."
  },
  {
   "question": "What is Merck & Co.'s (MRK) stock price forecast for 2030?",
   "answer": "Merck & Co.'s (MRK) long-range projection for 2030 estimates a base case price of $196.75, with a downside scenario at $108.05 and an upside scenario at $358.29. These figures are outcomes of a Monte Carlo simulation and not definitive price targets."
  },
  {
   "question": "What are the key technical levels for Merck & Co. (MRK)?",
   "answer": "Merck & Co. (MRK) is trading below its 20-day EMA of $145.34, indicating short-term weakness. Key support is found at the 50-day SMA of $136.68, while resistance is near the 20-day EMA. The RSI is significantly oversold at 22.65."
  },
  {
   "question": "What is the insider activity for Merck & Co. (MRK)?",
   "answer": "Insider activity for Merck & Co. (MRK) shows a heavy net sell signal, with $876.0M in total sales versus $1.6M in total purchases in recent filings. This indicates a lack of insider confidence in the stock's near-term prospects."
  },
  {
   "question": "How does Merck & Co. (MRK) compare to its sector averages?",
   "answer": "Merck & Co. (MRK) trades at a P/E ratio of 116.28, significantly higher than the Healthcare sector median of 31.9. Its profit margin of 4.77% is below the sector median of 6.9%, and its revenue growth of 5.1% is also lower than the sector median of 8.1%."
  },
  {
   "question": "What are the recent earnings results for Merck & Co. (MRK)?",
   "answer": "Merck & Co. (MRK) reported a positive EPS surprise of 50% for the quarter ending June 2026, with actual EPS of -$0.13 against an estimate of -$0.26. However, EPS estimates for the current and next quarters remain negative."
  },
  {
   "question": "What is the overall Wall Street sentiment for Merck & Co. (MRK)?",
   "answer": "Wall Street analysts maintain a 'Buy' consensus for Merck & Co. (MRK), with 15 Buy ratings and 8 Hold ratings out of 28 analysts. The median price target is $152.50, suggesting a potential 6.5% upside from the current price."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "RGNX",
    "name": "Regenxbio Inc. NASDAQ",
    "price": "$7.95",
    "change": "-8.57%",
    "url": "https://clearank.com/stock/rgnx-stock-analysis/"
   },
   {
    "ticker": "TLRY",
    "name": "Tilray Brands Inc. NASDAQ",
    "price": "$3.99",
    "change": "-3.62%",
    "url": "https://clearank.com/stock/tilray-brands-tlry/"
   },
   {
    "ticker": "RMD",
    "name": "ResMed Inc. NYSE",
    "price": "$229.44",
    "change": "+2.89%",
    "url": "https://clearank.com/stock/rmd-stock-analysis/"
   },
   {
    "ticker": "BSX",
    "name": "Boston Scientific Corp. NYSE",
    "price": "$43.87",
    "change": "-2.62%",
    "url": "https://clearank.com/stock/boston-scientific-bsx/"
   },
   {
    "ticker": "REPL",
    "name": "Replimune Group, Inc. NASDAQ",
    "price": "$13.03",
    "change": "-0.61%",
    "url": "https://clearank.com/stock/repl-stock-analysis/"
   },
   {
    "ticker": "VRTX",
    "name": "Vertex Pharmaceuticals Incorporated NASDAQ",
    "price": "$514.63",
    "change": "-0.94%",
    "url": "https://clearank.com/stock/vertex-vrtx/"
   },
   {
    "ticker": "CVS",
    "name": "CVS Health Corporation NYSE",
    "price": "$94.49",
    "change": "-1.11%",
    "url": "https://clearank.com/stock/cvs-health-cvs/"
   },
   {
    "ticker": "LEGN",
    "name": "Legend Biotech Corporation NASDAQ",
    "price": "$17.67",
    "change": "-4.64%",
    "url": "https://clearank.com/stock/legend-biotech-legn/"
   }
  ],
  "comparisons": [
   {
    "ticker": "PFE vs MRK Comparison",
    "name": "",
    "url": "https://clearank.com/compare/pfe-vs-mrk/"
   },
   {
    "ticker": "Junior Gold Miners (GDXJ) vs Silver Miners (SIL) Comparison",
    "name": "",
    "url": "https://clearank.com/compare/gdxj-vs-sil/"
   },
   {
    "ticker": "VGT vs SMH Comparison",
    "name": "",
    "url": "https://clearank.com/compare/vgt-vs-smh/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "EXC",
    "text": "Exelon Corp.",
    "url": "https://clearank.com/stock/exc-stock-analysis/"
   },
   {
    "ticker": "GWW",
    "text": "W.W. Grainger Inc.",
    "url": "https://clearank.com/stock/gww-stock-analysis/"
   },
   {
    "ticker": "CDE",
    "text": "Coeur Mining Inc.",
    "url": "https://clearank.com/stock/cde-stock-analysis/"
   },
   {
    "ticker": "CCI",
    "text": "Crown Castle Inc.",
    "url": "https://clearank.com/stock/cci-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "ARB/USD",
    "text": "↑ 19.42%",
    "url": "https://clearank.com/crypto/arbitrum-arb-usd/"
   },
   {
    "ticker": "INJ/USD",
    "text": "↓ 11.80%",
    "url": "https://clearank.com/crypto/injective-inj/"
   },
   {
    "ticker": "CRV/USD",
    "text": "↓ 11.53%",
    "url": "https://clearank.com/crypto/crv-usd-crypto-analysis/"
   },
   {
    "ticker": "CRCL",
    "text": "↓ 11.41%",
    "url": "https://clearank.com/stock/circle-internet-group-crcl/"
   },
   {
    "ticker": "TEM",
    "text": "↑ 10.67%",
    "url": "https://clearank.com/stock/tempus-ai-tem/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "GILD",
    "text": "Gilead Sciences",
    "url": "https://clearank.com/stock/gilead-sciences-gild/"
   },
   {
    "ticker": "JNJ",
    "text": "Johnson & Johnson",
    "url": "https://clearank.com/stock/johnson-johnson-jnj/"
   },
   {
    "ticker": "LLY",
    "text": "Eli Lilly",
    "url": "https://clearank.com/stock/eli-lilly-lly/"
   },
   {
    "ticker": "NVO",
    "text": "Novo Nordisk",
    "url": "https://clearank.com/stock/novo-nordisk-nvo/"
   },
   {
    "ticker": "PFE",
    "text": "Pfizer",
    "url": "https://clearank.com/stock/pfizer-pfe/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/06/merck-mrk.png",
     "url": "https://clearank.com/wp-content/uploads/2026/06/merck-mrk.png",
     "width": "1280",
     "height": "720",
     "caption": "Merck & Co. (MRK) stock price analysis chart for June 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/merck-mrk/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/merck-mrk/",
        "name": "Merck (MRK) Stock Price Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/merck-mrk/#webpage",
     "url": "https://clearank.com/stock/merck-mrk/",
     "name": "Merck (MRK) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-06-07T09:08:55+00:00",
     "dateModified": "2026-09-15T15:06:03+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/merck-mrk.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/merck-mrk/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/merck-mrk/#richSnippet",
     "headline": "Merck (MRK) Stock Forecast & Price Target (2026)",
     "name": "Merck (MRK) Stock Forecast & Price Target (2026)",
     "description": "Merck & Co., Inc. (MRK) stock: Healthcare, Drug Manufacturers - General. $357.4B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-06-07T09:08:55+00:00",
     "dateModified": "2026-09-15T15:06:03+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "Merck & Co., Inc.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "MRK"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NYSE"
       }
      ],
      "description": "Merck & Co., Inc. is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing medicines, vaccines, biologic therapies, and animal health products. The company’s pharmaceutical business serves areas such as oncology, immunology, infectious diseases, ca",
      "tickerSymbol": "MRK",
      "sameAs": "https://www.merck.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/merck-mrk/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/merck-mrk.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/merck-mrk/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "Is Merck & Co. (MRK) stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Merck & Co. (MRK) is currently rated as a Sell based on significant insider selling and oversold technical conditions. While Wall Street analysts have a 'Buy' consensus with a median price target of $152.50, the stock's high P/E ratio and negative operating margin present fundamental concerns."
     }
    },
    {
     "@type": "Question",
     "name": "What is Merck & Co.'s (MRK) stock price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Merck & Co.'s (MRK) long-range projection for 2030 estimates a base case price of $196.75, with a downside scenario at $108.05 and an upside scenario at $358.29. These figures are outcomes of a Monte Carlo simulation and not definitive price targets."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key technical levels for Merck & Co. (MRK)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Merck & Co. (MRK) is trading below its 20-day EMA of $145.34, indicating short-term weakness. Key support is found at the 50-day SMA of $136.68, while resistance is near the 20-day EMA. The RSI is significantly oversold at 22.65."
     }
    },
    {
     "@type": "Question",
     "name": "What is the insider activity for Merck & Co. (MRK)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Insider activity for Merck & Co. (MRK) shows a heavy net sell signal, with $72.4 million in total sales versus $0 in total purchases across 61 transactions. This indicates a lack of insider confidence in the stock's near-term prospects."
     }
    },
    {
     "@type": "Question",
     "name": "How does Merck & Co. (MRK) compare to its sector averages?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Merck & Co. (MRK) trades at a P/E ratio of 116.28, significantly higher than the Healthcare sector median of 31.9. Its profit margin of 4.77% is below the sector median of 6.9%, and its revenue growth of 5.1% is also lower than the sector median of 8.1%."
     }
    },
    {
     "@type": "Question",
     "name": "What are the recent earnings results for Merck & Co. (MRK)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Merck & Co. (MRK) reported a positive EPS surprise of 50% for the quarter ending June 2026, with actual EPS of -$0.13 against an estimate of -$0.26. However, EPS estimates for the current and next quarters remain negative."
     }
    },
    {
     "@type": "Question",
     "name": "What is the overall Wall Street sentiment for Merck & Co. (MRK)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Wall Street analysts maintain a 'Buy' consensus for Merck & Co. (MRK), with 15 Buy ratings and 8 Hold ratings out of 28 analysts. The median price target is $152.50, suggesting a potential 6.5% upside from the current price."
     }
    }
   ]
  }
 ]
}